Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Curtis Triplitt

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Diabetes|June 28, 2015
Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward SystemGiuseppe Daniele, Patricia Iozzo, Marjorie Molina-Carrion, et al.
Diabetes|January 10, 2020
Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 InhibitorsMariam Alatrach, Nitchakarn Laichuthai, Robert Martinez, et al.
The Journal of Clinical Endocrinology and Metabolism|December 17, 2024
Mesenteric Visceral Lipectomy (MVL) Improves Glucose Tolerance in Type 2 Diabetes Patients: A Pilot StudyGozde Baskoy, Richard Peterson, Jason Kempenich, et al.
Diabetes|October 24, 2024
Effect of Hyperketonemia on Myocardial Function in Patients With Heart Failure and Type 2 DiabetesCarolina Solis-Herrera, Yuejuan Qin, Henri Honka, et al.
Diabetes Care|March 8, 2020
Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose ExcretionCarolina Solis-Herrera, Giuseppe Daniele, Mariam Alatrach, et al.
Diabetes, Obesity & Metabolism|January 11, 2022
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)Olga Lavynenko, Muhammad Abdul-Ghani, Mariam Alatrach, et al.
Diabetes|January 5, 2008
Physiological and molecular determinants of insulin action in the baboonAlberto O Chavez, Juan C Lopez-Alvarenga, M Elizabeth Tejero, et al.
American Journal of Physiology. Endocrinology and Metabolism|June 20, 2022
FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetesRicardo J Samms, Christine C Cheng, Marcel Fourcaudot, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Diabetes|June 28, 2015
Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward SystemGiuseppe Daniele, Patricia Iozzo, Marjorie Molina-Carrion, et al.
Diabetes|January 10, 2020
Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 InhibitorsMariam Alatrach, Nitchakarn Laichuthai, Robert Martinez, et al.
The Journal of Clinical Endocrinology and Metabolism|December 17, 2024
Mesenteric Visceral Lipectomy (MVL) Improves Glucose Tolerance in Type 2 Diabetes Patients: A Pilot StudyGozde Baskoy, Richard Peterson, Jason Kempenich, et al.
Diabetes|October 24, 2024
Effect of Hyperketonemia on Myocardial Function in Patients With Heart Failure and Type 2 DiabetesCarolina Solis-Herrera, Yuejuan Qin, Henri Honka, et al.
Diabetes Care|March 8, 2020
Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose ExcretionCarolina Solis-Herrera, Giuseppe Daniele, Mariam Alatrach, et al.
Diabetes, Obesity & Metabolism|January 11, 2022
Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes (EDICT)Olga Lavynenko, Muhammad Abdul-Ghani, Mariam Alatrach, et al.
Diabetes|January 5, 2008
Physiological and molecular determinants of insulin action in the baboonAlberto O Chavez, Juan C Lopez-Alvarenga, M Elizabeth Tejero, et al.
American Journal of Physiology. Endocrinology and Metabolism|June 20, 2022
FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetesRicardo J Samms, Christine C Cheng, Marcel Fourcaudot, et al.
Pageof 6